{"brief_title": "Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke", "brief_summary": "This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.", "condition": "Intracerebral Hemorrhage", "intervention_type": "Drug", "intervention_name": "NXY-059", "criteria": "Inclusion Criteria: - Males and females - Intracerebral Hemorrhage as the cause of stroke symptoms - Onset of symptoms within 6 hours - Full functional independence prior to the present stroke Exclusion Criteria: - Unconsciousness - Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition. - Severe illness with life expectancy less than 6 months. - Known severe kidney disorder. - Current known alcohol or illicit drug abuse or dependence. - Pregnant or breast-feeding. - Treatment with acetazolamide and methotrexate is not permitted during the infusion - Participation in a previous clinical study within 7 days. - Meets all other exclusion criteria", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00075959.xml"}